Anti diarrheal medication for the treatment of diarrhea induced by the Ebola virus
|
|
- Gillian Clark
- 6 years ago
- Views:
Transcription
1 Anti diarrheal medication for the treatment of diarrhea induced by the Ebola virus The supportive care regimens used during the Ebola hemorrhagic fever outbreak in Kikwit, Democratic Republic of the Congo and subsequent outbreaks included the alleviation of nausea and vomiting (metoclopramide, promethazine), dyspepsia (aluminum hydroxide, cimetidine, ranitidine, omeprazole), anxiety, agitation, or confusion (diazepam, chlorpromazine), and pain (paracetamol, tramadol, and morphine). In addition to these medications, patients received oral fluid rehydration, nutritional supplementation, and psychosocial support. Despite the majority of patients having diarrhea, there is no mention of anti diarrheal medication use. 1 In a review of filovirus outbreaks, analgesics, antipyretics, and antiemetic s were typically available and administered as needed. Other symptomatic treatments occasionally available included antidiarrheals, sedatives, and antipsychotics to reduce anxiety and agitation. 2 An unknown amount of the 318 patients with reported Ebola virus infection in Yambuku, Zaire in 1976 received unspecified anti diarrheal medications. One patient in the U.K. in 1976 with EBV received diphenoxylate hydrochloride and atropine sulfate for diarrhea. All other cases up through 2011 either did not report using anti diarrheal medication or did not provide information on the clinical management of the patients. In general, non antibiotic anti diarrheal medications are not recommended for diarrhea associated with fever. It is also not recommended for mucous containing diarrhea marked by inflammation, ulceration, or bleeding of the gastrointestinal tract. 3 Other articles make broad statements such as loperamide may cause dangerous prolongation of illness in patients with some forms of bloody or inflammatory diarrhea and, therefore, should be restricted to patients with non bloody stool. A recent review article claims that the anti secretory drug bismuth subsalicylate is a safe alternative in patients with fever and inflammatory diarrhea, but cites an older paper specific to the use of diphenoxylate and atropine during shigellosis to make this claim. 4,5 Additionally, when an open label, parallel comparison study compared loperamide to bismuth subsalicylate in adults with acute, infectious diarrhea, there was a lower number of unformed bowel movements and a longer diarrhea free time period in the loperamide group. 6 Another review article claims, loperamide [should not be considered] in the treatment of a acute diarrhea when an infectious origin may be presumed. 7 However, this paper cites a retrospective casecontrol series specific to loperamide worsening a Clostridium difficile infection and extrapolates the results to any infectious diarrhea. 8 One randomized, controlled trial concluded that loperamide should be considered for the treatment of infectious diarrhea, so long as it is in combination with proper antibiotics for bacillary dysentery. 9 However, based on the findings of case report, if the underlying infectious condition progresses to a severe colitis, loperamide should be discontinued as it is associated with the development of toxic megacolon. 10 A single center, randomized, double blind trial assessed bismuth subsalicylate versus placebo in healthy volunteers inoculated with the Norwalk virus. Reduction in the severity and duration of abdominal cramps and duration of GI symptoms were improved in the treatment group. There was no difference in viral excretion into the stool. 11 Data on the use of anti diarrheal medication for the treatment of infectious diarrhea is mostly limited to bacterial sources. For viral gastroenteritis, short courses of anti diarrheal medications for mild to moderate episodes are used, with weak evidence of benefit and weak evidence of causing harm (e.g., constipation like periods). 12 There are also many trials of acute diarrhea treatment in which the cause
2 of diarrhea is unknown. Presuming some of these unknown causes are viral, there have never been any post hoc analyses performed to suggest inefficacy or harm when a virus was the cause. It is difficult to extrapolate results of the literature search to diarrhea induced by the Ebola virus to diarrhea associated with severe bacterial gastrointestinal infections. The key question is: In the pathophysiology of Ebola virus disease, does diarrhea play a protective role through elimination of the infectious agent? Cytomegalovirus (CMV) infection is known to cause diarrhea and hematochezia. CMV colitis has been treated with valganciclovir in combination with high doses (24 mg/day) of loperamide. 13 In CMV colitis diarrhea refractory to loperamide, multiple case reports exist to support the use of octreotide 50 mcg subcutaneously three times daily. {Teraishi, 2008, Cytomegalovirus colitis after systemic chemotherapy in a patient with recurrent colon cancer: a case report}{nomura, 2005, Severe cytomegalovirus enterocolitis after standard chemotherapy for non Hodgkin's lymphoma}{andrews, 2003, Octreotide treatment of massive hemorrhage due to cytomegalovirus colitis} 13 Despite these successful case reports, there is still concern that concomitant administration of an anti diarrheal agent could obscure the efficacy of antiviral treatment. To further complicate the issue, secondary bacterial infections in patients with Ebola virus disease occurs at an unknown incidence.{fowler, 2014, Caring for Critically Ill Patients with Ebola Virus Disease. Perspectives from West Africa} The concern is legitimate enough for most clinical treatment protocols to include the treatment of such infections. A source of such infections may be gastrointestinal bacterial translocation, a process which may theoretically be augmented by the use of anti motility agents. A leading physician in the field in West Africa during the most current outbreak indicates that current providers are uncomfortable and hesitant to use anti diarrheal medication. He indicates that it should be a clinical trial priority due to the volume of diarrhea and volume loss that occurs. (Robert Fowler, MD, e mail communication, 10/30/14). In the United States, diphenoxylate and atropine has been used to treat Ebola induced diarrhea. Providers were aware that there was no data for its use, but reasoned that since it has not been demonstrated that it is essential to eliminate the pathogen via diarrhea, it was reasonable to administer a few doses in the setting of careful patient monitoring. Subjectively, no benefit was reported, and abdominal distention may have resulted. (Andrew Faust, PharmD, ASHP Connect Ebola Community, 10/31/14). A systematic review of the treatment of diarrhea in adults was performed in One of the questions they sought to answer was What are the effects of treatment of severe diarrhea in resource poor countries? 12 Their review indicated that there are no systematic reviews or randomized controlled trials to evaluate the benefit or harm of treating severe diarrhea with anti motility agents. We performed a PubMed search of studies in the English language through September 2014 using combinations of the terms Ebola; diarrhea or gastroenteritis or colitis or hematochezia; and antidiarrheal or loperamide or bismuth subsalicylate or diphenoxylate and atropine or octreotide or gastroenteritis or colitis. This search did not provide any evidence of trials that have addressed this question before. Therefore, the treatment of Ebola induced diarrhea will have to be based on clinical judgment with full assessment of the benefits and risks of using such therapies. Clinicians should consider the use of loperamide and/or diphenoxylate and atropine for mild to moderate Ebola induced diarrhea and also consider the addition of octreotide for the use of severe, life threatening Ebola
3 induced diarrhea. Very careful monitoring of patients should be performed with discontinuation of therapy should abdominal distention or other suspected adverse events arise. A clinical trial of antidiarrheal medication for the treatment of Ebola induced diarrhea is clinically warranted. References 1. Roddy P, Howard N, Van Kerkhove MD, et al. Clinical manifestations and case management of Ebola haemorrhagic fever caused by a newly identified virus strain, Bundibugyo, Uganda, PLoS One 2012;7:e Clark DV, Jahrling PB, Lawler JV. Clinical management of filovirus infected patients. Viruses 2012;4: DuPont HL. Acute infectious diarrhea in immunocompetent adults. N Engl J Med 2014;370: Barr W, Smith A. Acute diarrhea. Am Fam Physician 2014;89: DuPont HL, Hornick RB. Adverse effect of lomotil therapy in shigellosis. Jama 1973;226: DuPont HL, Flores Sanchez J, Ericsson CD, et al. Comparative efficacy of loperamide hydrochloride and bismuth subsalicylate in the management of acute diarrhea. Am J Med 1990;88:15s 9s. 7. Franceschi F, Scaldaferri F, Riccioni ME, et al. Management of acute dyarrhea: current and future trends. Eur Rev Med Pharmacol Sci 2014;18: Kato H, Iwashima Y, Nakamura M, Nakamura A, Ueda R. Inappropriate use of loperamide worsens Clostridium difficile associated diarrhoea. J Hosp Infect. England2008: Murphy GS, Bodhidatta L, Echeverria P, et al. Ciprofloxacin and loperamide in the treatment of bacillary dysentery. Ann Intern Med 1993;118: Brown JW. Toxic megacolon associated with loperamide therapy. Jama 1979;241: Steinhoff MC, Douglas RG, Jr., Greenberg HB, Callahan DR. Bismuth subsalicylate therapy of viral gastroenteritis. Gastroenterology 1980;78: de Bruyn G. Diarrhoea in adults (acute). Clin Evid (Online) 2008; Bartels MC, Mergenhagen KA. Octreotide for symptomatic treatment of diarrhea due to cytomegalovirus colitis. Ann Pharmacother 2011;45:e4. Author : Ron Kendall, PharmD, PGY 2 ID
4 Reference Population Studied Intervention Outcomes Limitations DuPont et. al. JAMA healthy, adult male inmate volunteers in Jessup, MD Brown. JAMA of a 24 year old female with ulcerative colitis Steinhoff et al. Gastroenterol Graham et al. Gastroenterol DuPont et al. Am J Med Young, healthy volunteers in Rochester, NY Healthy, hospitalized volunteers in Houston, TX Young adults in California and Arizona Volunteers were inoculated with Shigella flexneri and all who developed diarrhea were receive diphenoxylate and atropine or placebo and oxolinic acid or placebo. Patient received 8 days of prednisone and loperamide 12 mg/day Volunteers were inoculated with the Norwalk virus, and were then receive bismuth subsalicylate or placebo Volunteers were inoculated with enterotoxigenic E. coli (ETEC) strain H10407 and were then receive bismuth subsalicylate or placebo Subjects were enrolled if they had Fever was prolonged in patients who received only diphenoxylate and atropine. Shigella was eradicated from the stool in 4 out of 6 men treated with oxolinic acid alone, but only 1 out of 6 men treated with oxolinic acid and diphenoxylate and atropine. Toxic megacolon developed. Statistically significant reduction in severity and duration of abdominal cramps and duration of GI symptoms occurred in the treatment group. Study did not have enough outcomes to support or disprove whether or not bismuth subsalicylate is useful to treat diarrhea induced by ETEC. Loperamide reduced diarrhea significantly more than bismuth Single center. Small sample size. Single case report. Single center. Small sample size. Single center. Small sample size. Small observation period of 48 hours.
5 Murphy et al. Ann Intern Med Andrews et al. Can J Gastroenterol Nomura et al. Scand J Gastroenterol with recent travel to Guadalajara, Mexico Thailand, , patients with dysentery diagnosed by 3 or more stools with blood or mucus with either cramps, nausea, vomiting, or temperature > 38 C for fewer than 60 hours. Exclusion: antimotility agent or antibiotics in previous 7 days, pregnancy, immunosuppression, or lack of follow up for 10 days. acute (less than 72 hours) of non specific diarrhea plus one other symptom of enteric infection. They were be treated with loperamide or bismuth subsalicylate for 48 hours. Patients were receive ciprofloxacin 500 mg PO BID x 3 days plus either placebo or loperamide 4 mg initial dose plus 2 mg after every loose stool (maximum 16 mg per day). CMV colitis diagnosed by histopathology after 5 days of bloody diarrhea treated with octreotide. CMV enterocolitis unresponsive to subsalicylate. Loperamide provided better subjective relief than bismuth subsalicylate. There were only minor adverse effects, none leading to discontinuation of therapy. Median daily stools was fewer in the loperamide group 4.5 vs. 7 (P = 0.03). Subgroup analysis of patients with Shigella or enteroinvase E. coli found patients in the loperamide group had 19 (6 42) hours of diarrhea vs. 42 (21 46) hours in placebo (P = 0.028) and fewer diarrheal stools after treatment 2 (1 5) vs. 6.5 (2 9) (P=0.016). Blood loss stopped almost immediately and no further transfusions were required. Diarrhea rapidly improved over the next 2 days and then ceased. Single center. Due to low patient enrollment, the study was extended in order to enroll enough patients. Single case report. Temporal association, rather than direct cause and effect. Single case report. Temporal association, rather than
6 Kato et al. J Hosp Infect Teraishi et al. J Med Case Report Bartels et al. Ann Pharmacother Japan, 2003, Clostridium difficile (CD) infection diagnosed by stool culture or diarrhea with a positive CD toxin A. All patients were treated with oral vancomycin. ganciclovir and foscarnet was treated with the addition of octreotide 100 mcg IM daily. Compared clinical records of patients with Clostridium difficile associated diarrhea treated with loperamide (6 patients) with 80 control cases without loperamide. CMV colitis was treated with ganciclovir and octreotide 200 mcg/day subcutaneously for 10 days CMV colitis treated with oral valgancyclovir and loperamide 24 mg/day, followed by IV ganciclovir and loperamide 8 mg/day, followed by the addition of octreotide 50 mcg subcutaneously every 8 hours. Duration of diarrhea more than twice a day was 9.0 +/ 0.9 days vs / 3.3 days (P < 0.001) favoring no loperamide. Maximum episodes of diarrhea per day was 9.2 +/ 4.3 episodes vs / 2.8 episodes (P < 0.005) in favor of no loperamide. Duration of disease was / 8.9 days vs / 2.8 days in favor of no loperamide (P < 0.05). Patient gradually improved, with multiple ulcers demonstrating partial healing on 4 week repeat colonoscopy. Diarrhea improved within a few days of starting octreotide. CMV colitis resolved later that month. direct cause and effect. Small sample size. Retrospective design. Single case report. Temporal association, rather than direct cause and effect. Single case report. Temporal association, rather than direct cause and effect.
7
Rifaximin for Travellers Diarrhoea
New Medicines Profile April 2013 Issue No. 13.01 for Travellers Diarrhoea Concise evaluated information to support the managed entry of new medicines in the NHS Summary is a broad spectrum antibiotic licensed
More informationImmodium / loprarmide
Immodium / loprarmide IMODIUM (loperamide hydrochloride) is indicated for the control and symptomatic relief of acute nonspecific diarrhea and of chronic diarrhea associated with inflammatory bowel disease.
More informationClostridium Difficile Infection in Adults Treatment and Prevention
Clostridium Difficile Infection in Adults Treatment and Prevention Definition: Clostridium Difficile colonizes the human intestinal tract after the normal gut flora has been altered by antibiotic therapy
More informationENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE
ENGLISH FOR PROFESSIONAL PURPOSES UNIT 3 HOW TO DEAL WITH CLOSTRIDIUM DIFFICILE The diagnosis of CDI should be based on a combination of clinical and laboratory findings. A case definition for the usual
More informationAlgorithms & Information Sheets
Minor Ailment Scheme Algorithms & Information Sheets Acute Diarrhoea Diarrhoea is an increased frequency, fluidity or volume of the bowel movements with the passage of soft and watery stools as compared
More informationUpdates to pharmacological management in the prevention of recurrent Clostridium difficile
Updates to pharmacological management in the prevention of recurrent Clostridium difficile Julia Shlensky, PharmD PGY2 Internal Medicine Resident September 12, 2017 2017 MFMER slide-1 Clinical Impact Increasing
More informationProtectives and Adsorbents. Inorganic chemistry Course 1 Third year Assist. Lecturer Ahlam A. Shafeeq MSc. Pharmaceutical chemistry
Protectives and Adsorbents Inorganic chemistry Course 1 Third year 2016-2017 Assist. Lecturer Ahlam A. Shafeeq MSc. Pharmaceutical chemistry Protectives and Adsorbents This group of gastrointestinal agents
More information! Macrolide antibacterial. Fidaxomicin (Dificid ) package labeling. Optimer Pharmaceuticals, Inc. May 2011.
Disclosure! I have no conflicts of interest related to this presentation Nina Naeger Murphy, Pharm.D., BCPS Clinical Pharmacy Specialist Infectious Diseases MetroHealth Medical Center Learning Objectives!
More informationTravellers Diarrhea Update: From Prevention to Self-Treatment. Michael Payne November 4 th, 2016
Travellers Diarrhea Update: From Prevention to Self-Treatment Michael Payne November 4 th, 2016 Outline 1. Epidemiology of travellers diarrhea 2. Prevention Behavioral Vaccination Medications 3. Self-treatment
More informationAcute Gastroenteritis, Adult Emergency Orders
Form Title Form Number 21003 2018, Alberta Health Services, CKCM This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. The license does not
More informationLabeled Uses: Treatment of Clostiridum Difficile associated diarrhea (CDAD)
Brand Name: Dificid Generic Name: fidaxomicin Manufacturer 1,2,3,4,5 : Optimer Pharmaceuticals, Inc. Drug Class 1,2,3,4,5 : Macrolide Antibiotic Uses 1,2,3,4,5 : Labeled Uses: Treatment of Clostiridum
More informationREFERENCE NUMBER: NH.PMN.47 EFFECTIVE DATE: 11/11
PAGE: 1 of 5 RETIRED: REVIEWED: 11/11, 12/14, 08/16, 07/17 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough
More informationGI Bacterial Infections (part-1)
GI Bacterial Infections (part-1) Mohammed Abdulla Mehdi FIBMS (internal medicine), FIBMS (Gastroenterology & Hepatology) Acute diarrhea and vomiting Acute diarrhea, sometimes with vomiting, is the predominant
More informationUnderstanding the Benefits and Risks
LOTRONEX and its authorized generic alosetron hydrochloride: Understanding the Benefits and Risks The LOTRONEX REMS Program Prescriber Education Slide Deck LOTRONEX is a registered trademark of Prometheus
More informationGastroenteritis. Presenter: J.J. Kambona (M.B.Ch.B; M.Med)
Gastroenteritis Presenter: J.J. Kambona (M.B.Ch.B; M.Med) OBJECTIVES At the end of this session each student will be able to: 1. Define gastroenteritis, diarrhoea and loose stool. 2. Classify diarrhoea.
More informationLOTRONEX and its authorized generic alosetron hydrochloride:
LOTRONEX and its authorized generic alosetron hydrochloride: Understanding the Benefits and Risks The Prescribing Program for LOTRONEX TM Prescriber Education Slide Deck PROMETHEUS and the Link Design
More informationGI Bacterial Infections (part-2)
GI Bacterial Infections (part-2) Mohammed Abdulla Mehdi FIBMS (internal medicine), FIBMS (G&H) Clostridium difficile infection C. difficile is the most commonly diagnosed cause of antibioticassociated
More informationClostridium difficile Infection (CDI) Management Guideline
Clostridium difficile Infection (CDI) Management Guideline Do not test all patients with loose or watery stools for CDI o CDI is responsible for
More informationGeneral Medical Concerns
General Medical Concerns General Medical Concerns Fred Reifsteck MD Head Team Physician University of Georgia Missed Time: school, work, practice, games Decreased Performance Physical/ Mental stress: New
More informationBacterial Enteric Pathogens: Clostridium difficile, Salmonella, Shigella, Escherichia coli, and others
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 48 Bacterial Enteric Pathogens: Clostridium difficile, Salmonella, Shigella, Escherichia coli, and others Authors Olivier Vandenberg, MD, PhD Michèle
More informationIs one of the most common chronic disorders. causing patients to seek medical treatment.
ILOs After this lecture you should be able to : Define IBS Identify causes and risk factors of IBS Determine the appropriate therapeutic options for IBS Is one of the most common chronic disorders causing
More information(Data from the Travel Health Surveillance Section of the Health Protection Agency Communicable Disease Surveillance Centre)
Travellers Diarrhoea Introduction Travellers diarrhoea (TD) is a syndrome that commonly affects travellers caused by one of several different organisms, the most common being enterotoxigenic Escherichia
More informationCommunicable diseases. Gastrointestinal track infection. Sarkhell Araz MSc. Public health/epidemiology
Communicable diseases Gastrointestinal track infection Sarkhell Araz MSc. Public health/epidemiology Communicable diseases : Refer to diseases that can be transmitted and make people ill. They are caused
More informationClinical Policy: Alosetron (Lotronex) Reference Number: CP.CPA.65 Effective Date: Last Review Date: Line of Business: Medicaid Medi-Cal
Clinical Policy: (Lotronex) Reference Number: CP.CPA.65 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationCytomegalovirus Colitis in an Immunocompetent Patient: A Case Report
ISPUB.COM The Internet Journal of Surgery Volume 17 Number 2 Cytomegalovirus Colitis in an Immunocompetent Patient: A Case Report M Ud Citation M Ud. Cytomegalovirus Colitis in an Immunocompetent Patient:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Lotronex) Reference Number: CP.PMN.153 Effective Date: 11.16.16 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationDrugs Affecting the Gastrointestinal System. Antidiarrheal and Laxatives
Drugs Affecting the Gastrointestinal System Antidiarrheal and Laxatives Diarrhea Abnormal frequent passage of loose stools or Abnormal passage of stools with increased frequency, fluidity, and weight,
More informationClass Review: Antidiarrheals
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationHandbook of Nonprescription Drugs: An Interactive Approach to Self Care, 18 th Edition Corrections and Revisions
Handbook of Nonprescription Drugs: An Interactive Approach to Self Care, 18 th Edition Corrections and Revisions Note: All the corrections and revisions have been made on the e version of the book that
More informationManagement of the Hospitalized IBD Patient. Drew DuPont MD
Management of the Hospitalized IBD Patient Drew DuPont MD Ulcerative Colitis: Indications for Admission Severe ulcerative colitis Frequent loose bloody stools ( 6 per day) Severe cramps Systemic toxicity:
More informationMedical Treatment for Microscopic Colitis: A Community Hospital s Experience
Original Article Gastroenterol Res. 2017;10(6):329-333 Medical Treatment for Microscopic Colitis: A Community Hospital s Experience Abdallah Haidar a, d, Savreet Kaur a, Nancy Jackson b, Jose Mari Parungao
More informationXifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary
Xifaxan, Lotronex and Viberzi Prior Authorization and Quantity Limit Program Summary FDA APPROVED INDICATIONS DOSAGE 1,2 Lotronex (alosetron) a Indication For women with severe diarrheapredominant irritable
More informationComparative Evaluation of Efficacy of Antibiotic in Treating Bacterial Enteritis in Children: A Hospital Based Study
Original article: Comparative Evaluation of Efficacy of Antibiotic in Treating Bacterial Enteritis in Children: A Hospital Based Study Radheshyam Shrotriya, Anju Kochar Principal Specialist (Pediatrics),
More informationClass Review: Antidiarrheals
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPembrozulimab Induced Collagenous Colitis. Mokshya Sharma 1, MD, Santhosh Ambika 2, MD University of Nevada, Reno SOM
Pembrozulimab Induced Collagenous Colitis Mokshya Sharma 1, MD, Santhosh Ambika 2, MD University of Nevada, Reno SOM Background Immune modulating therapy that targets PD1 pathway such as pembrozulimab
More informationStudy on Incidence of Antibiotic Associated Diarrhoea in General Paediatric Ward
HK J Paediatr (new series) 2002;7:33-38 Study on Incidence of Antibiotic Associated Diarrhoea in General Paediatric Ward CM HUI, K TSE Abstract Objective: To estimate the incidence rate and risk factors
More informationA Pharmacist Perspective
Leveraging Technology to Reduce CDI A Pharmacist Perspective Ed Eiland, Pharm.D., MBA, BCPS (AQ-ID) Clinical Practice and Business Supervisor Huntsville Hospital System Huntsville Hospital 881 licensed
More information9/18/2018. Clostridium Difficile: Updates on Diagnosis and Treatment. Clostridium difficile Infection (CDI) Clostridium difficile Infection (CDI)
Clostridium Difficile: Updates on Diagnosis and Treatment Elizabeth Hudson, DO, MPH 9/25/18 Antibiotic-associated diarrhea and colitis were well established soon after widespread use of antibiotics In
More informationWhat is Irritable Bowel Syndrome (IBS)?
What is Irritable Bowel Syndrome (IBS)? Irritable bowel syndrome (IBS) is a health issue found in your intestines (gut). IBS can cause symptoms such as: Belly pain. Cramping. Gas. Bloating (or swelling)
More informationLong-Term Care Updates
Long-Term Care Updates April 2017 Bezlotoxumab to Prevent Recurrent Infection By Amy Wilson, PharmD and Zara Risoldi Cochrane, PharmD, MS, FASCP Introduction The Gram-positive bacteria is a common cause
More informationChapter 32 Gastroenterology General Pathophysiology General Risk Factors for GI emergencies: Excessive Consumption Excessive Smoking Increased
1 2 3 4 5 6 7 Chapter 32 Gastroenterology General Pathophysiology General Risk Factors for GI emergencies: Excessive Consumption Excessive Smoking Increased Ingestion of Caustic Substances Poor Bowel Habits
More informationACUTE GASTROENTERITIS IN CHILDREN
ACUTE GASTROENTERITIS IN CHILDREN Prof. Alok Kumar Professor of Pediatrics & Infectious Diseases Faculty of Medical Sciences The University of the West Indies (Cave Hill) 11/6/2017 1 DEFINITION Gastroenteritis
More information15/05/2015. No conflict of interest for this presentation. The first in-class phosphotidlyinositol3-kinase delta (PI3K delta) inhibitor
Disclosure Idelalisib - A Review No conflict of interest for this presentation Pamela Rudkin PhC Hematology Oncology Pharmacist General Hospital Site Eastern Health Care Corporation Objectives At the completion
More informationABSTRACT PURPOSE METHODS
ABSTRACT PURPOSE The purpose of this study was to characterize the CDI population at this institution according to known risk factors and to examine the effect of appropriate evidence-based treatment selection
More informationViral gastroenteritis Gastrointestinal infections caused by viruses are the most common and the most contagious.3
CMA Today Quick Clinic May/Jun 2017 (Issue 3/Volume 50) GI woes Gastroenteritis affects patients at home and abroad By Nancy Solomon We expect patients to come into the office a few times a year with that
More informationCLOSTRIDIUM DIFICILE. Negin N Blattman Infectious Diseases Phoenix VA Healthcare System
CLOSTRIDIUM DIFICILE Negin N Blattman Infectious Diseases Phoenix VA Healthcare System ANTIBIOTIC ASSOCIATED DIARRHEA 1978: C diff first identified 1989-1992: Four large outbreaks in the US caused by J
More informationDeveloped September Revised May 2018; June 2017; June 2015; October 2013; December 2011; April 2010; December 2006.
Texas Vendor Drug Program Drug Use Criteria: Rifaximin (Xifaxan ) Publication History Developed September 2006. Revised May 2018; June 2017; June 2015; October 2013; December 2011; April 2010; December
More informationCrohn's Disease. What causes Crohn s disease? What are the symptoms?
Crohn's Disease Crohn s disease is an ongoing disorder that causes inflammation of the digestive tract, also referred to as the gastrointestinal (GI) tract. Crohn s disease can affect any area of the GI
More information... Inflammatory disorder of the colon that occurs as a complication of antibiotic treatment.
Definition Inflammatory disorder of the colon that occurs as a complication of antibiotic treatment. " Epidemiology Humans represent the main reservoir of Clostridium difficile, which is not part of the
More informationTrue Pathogens of the Enterobacteriaceae: Salmonella, Shigella & Yersinia Salmonella
Lec. 6 Oral Microbiology Dr. Chatin True Pathogens of the Enterobacteriaceae: Salmonella, Shigella & Yersinia Salmonella General Characteristics of Salmonella جامعة تكريت كلية طب االسنان Coliform bacilli
More informationIBS. Patient INFO. A Guide to Irritable Bowel Syndrome
Patient INFO IBS A Guide to Irritable Bowel Syndrome The information provided by the AGA Institute is not medical advice and should not be considered a replacement for seeing a medical professional. About
More informationLESSON ASSIGNMENT. Emetics, Antiemetics, and Antidiarrheals. After completing this lesson, you should be able to:
LESSON ASSIGNMENT LESSON 3 Emetics, Antiemetics, and Antidiarrheals. LESSON ASSIGNMENT Paragraphs 3-1 through 3-8. LESSON OBJECTIVES After completing this lesson, you should be able to: 3-1. Given one
More informationYao Rong, MD, PhD. Emergency Department of West China Hospital
Yao Rong, MD, PhD Emergency Department of West China Hospital Diarrhea Normal : Stool weight : 100 ~ 200 g bowel frequency : 3 times a week ~ 3 times a day 2 Diarrhea An increase in the volume of stool
More informationDISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest wit
GASTROENTERITIS DISCLOSURE Relevant relationships with commercial entities Wyeth (received advisory board & speaker honoraria) Potential for conflicts of interest within this presentation fidaxomicin (which
More informationEDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE
EDUCATIONAL COMMENTARY CLOSTRIDIUM DIFFICILE UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits click
More informationDear Healthcare Provider, The information contained here may be very important to your practice. Please take a moment to review this document.
February 2018 Dear Healthcare Provider, The information contained here may be very important to your practice. Please take a moment to review this document. TEST BULLETIN CHLAMYDIA/GONORRHEA SPECIMEN COLLECTION
More informationCYP2C19-Proton Pump Inhibitors
CYP2C19-Proton Pump Inhibitors Cameron Thomas, Pharm.D. PGY2 Clinical Pharmacogenetics Resident St. Jude Children s Research Hospital February 1, 2018 Objectives: CYP2C19-PPI Implementation Review the
More information-2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine. -June 2008: Recurrence of rectal blood loss and urgency
SD, male 40 yrs. old. (680718M467.) -2002: Rectal blood loss, UC? (no definite diagnosis) rectal mesalazine -June 2008: Recurrence of rectal blood loss and urgency Total colonoscopy: ulcerative rectitis,
More informationDiarrhoea on the AMU. Dr Chris Roseveare
Diarrhoea on the AMU Dr Chris Roseveare The Society for Acute Medicine, Spring Meeting, Radisson Blu Hotel, Dublin 3-4 May 2012 Acute diarrhoea in developed countries adult populations Mainly a primary
More informationChristina Tennyson, M.D. Division of Gastroenterology
Diarrhea Christina Tennyson, M.D. Assistant Professor of Medicine Division of Gastroenterology Columbia University DIARRHEA Symptom: stool frequency, liquidity Sign: > 200-250 g/day Acute Chronic Time
More information2/26/2009. Diarrhea. Christina Tennyson, M.D. Assistant Professor of Medicine Division of Gastroenterology Columbia University
Diarrhea Christina Tennyson, M.D. Assistant Professor of Medicine Division of Gastroenterology Columbia University 1 Symptom: Sign: DIARRHEA stool frequency, liquidity > 200-250 g/day Acute Chronic Time
More informationCHRONIC DIARRHEA DR. PHILIP K. BLUSTEIN M.D. F.R.C.P.(C) DEFINITION: *LOOSE, WATERY STOOLS *MORE THAN 3 TIMES A DAY *FOR MORE THAN 4 WEEKS
DR. PHILIP K. BLUSTEIN M.D. F.R.C.P.(C) 415 14 TH ST. NW. CALGARY AB T2N2A1 PHONE (403) 270-9555 FAX (403) 270-7479 CHRONIC DIARRHEA DEFINITION: *LOOSE, WATERY STOOLS *MORE THAN 3 TIMES A DAY *FOR MORE
More informationManaging Checkpoint Inhibitor Toxicities. Megan L. Menon, Pharm.D., BCOP Roswell Park Cancer Institute
Managing Checkpoint Inhibitor Toxicities Megan L. Menon, Pharm.D., BCOP Roswell Park Cancer Institute Approved Indications Ipilimumab Nivolumab Pembrolizumab* Atezolizumab Avelumab Durvalumab Ipi + Nivol
More informationIBS - Definition. Chronic functional disorder of GI generally characterized by:
IBS - Definition Chronic functional disorder of GI generally characterized by: 3500 3000 No. of Publications 2500 2000 1500 1000 Irritable Bowel syndrome Irritable Bowel Syndrome 500 0 1968-1977 1978-1987
More informationCertain genes passed on from parent to child increase the risk of developing Crohn's disease, if the right trigger occurs.
Topic Page: Crohn's disease Definition: Crohn's disease from Benders' Dictionary of Nutrition and Food Technology Chronic inflammatory disease of the bowel, commonly the terminal ileum, of unknown aetiology,
More informationPrevention of Travelers Diarrhea With Rifaximin in US Travelers to Mexico
I S T M 111 Prevention of Travelers Diarrhea With Rifaximin in US Travelers to Mexico Francisco Martinez-Sandoval, MD, PhD, Charles D. Ericsson, MD, Zhi-Dong Jiang, MD, PhD, Pablo C. Okhuysen, MD, Juan
More informationCONTROL OF VIRAL GASTROENTERITIS OUTBREAKS IN CALIFORNIA LONG-TERM CARE FACILITIES
CONTROL OF VIRAL GASTROENTERITIS OUTBREAKS IN CALIFORNIA LONG-TERM CARE FACILITIES California Department of Health Services Division of Communicable Disease Control In Conjunction with Licensing and Certification
More informationAtypical Presentation of Clostridium Difficille Infection (CDI).
Article ID: WMC004648 ISSN 2046-1690 Atypical Presentation of Clostridium Difficille Infection (CDI). Peer review status: No Corresponding Author: Dr. Syed A Gardezi, CT1, Medicine,NevillHall Hospital
More informationUpdated Clostridium difficile Treatment Guidelines
Updated Clostridium difficile Treatment Guidelines Arielle Arnold, PharmD, BCPS Clinical Pharmacist Saint Alphonsus Regional Medical Center September 29 th, 2018 Disclosures Nothing to disclose Learning
More informationAlberta Health and Wellness Public Health Notifiable Disease Management Guidelines August 2011
August 2011 Campylobacteriosis Revision Dates Case Definition Reporting Requirements Remainder of the Guideline (i.e., Etiology to References sections inclusive) August 2011 August 2011 October 2005 Case
More informationCROHN S DISEASE. The term "inflammatory bowel disease" includes Crohn's disease and the other related condition called ulcerative colitis.
CROHN S DISEASE What does it consist of? Crohn s disease is an inflammatory process that affects mostly to the intestinal tract, although it can affect any other part of the digestive apparatus from the
More informationGASTROINTESTINAL AND ANTIEMETIC DRUGS. Submitted by: Shaema M. Ali
GASTROINTESTINAL AND ANTIEMETIC DRUGS Submitted by: Shaema M. Ali GASTROINTESTINAL AND ANTIEMETIC DRUGS by: Shaema M. Ali There are four common medical conditions involving the GI system 1) peptic ulcers
More informationEbola Virus Patient Advisory
22 September 2014 Ebola Virus Patient Advisory Introduction Ebola virus was first identified in Sudan and Zaire in 1976. It belongs to the family of Filoviridae. It causes Ebola Virus Disease (EVD), formerly
More informationInflammatory Bowel Disease
+ Inflammatory Bowel Disease Christina Kalafsky, Dietetic Intern University of Maryland College Park Children s National Medical Center Case Study January 31, 2014 + Outline n Inflammatory Bowel Disease
More informationGastroenteritis Outbreaks Including Norovirus. Module 7
Gastroenteritis Outbreaks Including Norovirus Module 7 Learner Outcomes By the end of this module you will be able to: Outline the case definition for a gastroenteritis outbreak. Explain the difference
More informationColon ischemia. Bible class 12 September Stefan Christen. ACG Clinical Guideline: Am J Gastroenterol 2015
Colon ischemia Bible class 12 September 2018 Stefan Christen ACG Clinical Guideline: Am J Gastroenterol 2015 Definition Definition Imbalance between blood supply and metabolic demands of the colonocytes
More informationmore intense treatments are needed to get rid of the infection.
What Is Clostridium Difficile (C. Diff)? Clostridium difficile, or C. diff for short, is an infection from a bacterium that can grow in your intestines and cause bad GI symptoms. The main risk of getting
More informationPthaigastro.org. Drugs Used in Acute Diarrhea: Cons. Nipat Simakachorn, M.D. Department of Pediatrics Maharat Nakhon Ratchasima Hospital.
Drugs Used in Acute Diarrhea: Cons Nipat Simakachorn, M.D. Department of Pediatrics Maharat Nakhon Ratchasima Hospital 27-Apr-2012 Optimistic Pessimistic Global percentage of children
More informationThe Potential For Microbiome Modification In Critical Illness. Deborah Cook
The Potential For Microbiome Modification In Critical Illness Deborah Cook To review Objectives The microbiome & concepts about its modification during critical illness Interventions Predisposition to
More informationHompes Method. Practitioner Training Level II. Lesson Seven Part A DRG Pathogen Plus Interpretation
Hompes Method Practitioner Training Level II Lesson Seven Part A DRG Pathogen Plus Interpretation Health for the People Ltd not for reuse without expressed permission Hompes Method is a trading name of
More information33. I will recommend this primer to my colleagues. A. Strongly Agree D. Disagree B. Agree E. Strongly Disagree C. Neither agree nor disagree
27. The primer increased my ability to recognize foodborne illnesses and increased the likelihood that I will consider such illnesses in my patients. 28. The primer increased my knowledge and skills in
More informationPost-Infectious Irritable Bowel Syndrome. John K. Marshall MD Division of Gastroenterology McMaster University
Post-Infectious Irritable Bowel Syndrome John K. Marshall MD Division of Gastroenterology McMaster University Pathogenesis of IBS Enck P. Nat Rev Dis Primers 2016;2:16014 Post-Infectious Irritable Bowel
More informationGastroenteritis. Mohamed Ahmed Fouad Lecturer of pediatrics Jazan faculty of medicine
Gastroenteritis Mohamed Ahmed Fouad Lecturer of pediatrics Jazan faculty of medicine Objectives Review the epidemiology and most common etiologies of diarrhea Discuss specific characteristics of most
More informationTitle: Public Health Reporting and National Notification for Shigellosis
11-ID-19 Committee: Infectious Title: Public Health Reporting and National Notification for Shigellosis I. Statement of the Problem Currently, case confirmation for Shigellosis is dependent on isolation
More informationLearning Objectives. A Critical Analysis of Recent Fidaxomicin & Nesiritide Trials. Fidaxomicin vs. Vancomycin. Outline 1/3/2012
Learning Objectives A Critical Analysis of Recent Fidaxomicin & Nesiritide Trials Amy E. Lodolce, PharmD, BCPS Assistant Director, Drug Information Group UIC College of Pharmacy Describe the methods and
More informationSecond term/
Second term/ 2015-2016 L. 1 Dr Mohammed AL-Zobaidy Learning objectives GIT pharmacology After completing this chapter the student will be able to: Recognise pathophysiological factors implicated in acid-peptic
More informationDivision of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013
Division of GIM Lecture Series Case Presentation David A. Erickson, M.D October 9th, 2013 Financial Disclosures No financial disclosures Objectives Review a case of recurrent Clostridium difficile infection
More informationClinical approach to evaluate infectious diarrhea. Diarrhea. Defect Stool exam Examples mechanism. stool
Clinical approach to evaluate infectious diarrhea Diarrhea Mechanism Clinical manifestation Having three of more loose or liquid stools per day, or having more stools than normal for that person 1ry Defect
More informationSTUDENTS IN MEXICO*,**,t
EMPORIATRIC ENTERITIS: LESSONS LEARNED FROM U.S. STUDENTS IN MEXICO*,**,t HERBERT L. DUPONT and (by invitation) CHARLES D. ERICSSON and MARGARET W. DUPONT HOUSTON Between 15 and 20 million persons annually
More informationMarburg virus disease
Marburg virus disease Fact sheet available at http://www.who.int/mediacentre/factsheets/fs_marburg/en/ Updated 20 October 2017 Key facts Marburg virus disease (MVD), formerly known as Marburg haemorrhagic
More informationThe incubation period is unknown. However; the onset of clinical disease is typically 5-10 days after initiation of antimicrobial treatment.
C. DIFFICILE Case definition CONFIRMED CASE A patient is defined as a case if they are one year of age or older AND have one of the following requirements: A laboratory confirmation of a positive toxin
More informationDiagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review
Diagnosis, Management, and Prevention of Clostridium difficile infection in Long-Term Care Facilities: A Review October 18, 2010 James Kahn and Carolyn Kenney, MSIV Overview Burden of disease associated
More information8/29/2016 DIVERTICULAR DISEASE: WHAT EVERY NURSE PRACTITIONER SHOULD KNOW. LENORE LAMANNA Ed.D, ANP-C LEARNING OBJECTIVES
DIVERTICULAR DISEASE: WHAT EVERY NURSE PRACTITIONER SHOULD KNOW LENORE LAMANNA Ed.D, ANP-C LEARNING OBJECTIVES Define Diverticular Disease Discuss Epidemiology and Pathophysiology of Diverticular disease
More informationLiterature Scan: Antibiotics for Clostridium difficile Infection. Month/Year of Review: May 2015 Date of Last Review: April 2012
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAn Outbreak of Gastroenteritis Among Warehouse Workers
Centers for Disease Control and Prevention Case Studies in Applied Epidemiology No. 055-710 An Outbreak of Gastroenteritis Among Warehouse Workers Participant s Guide Learning Objectives After completing
More informationChapter 34. Nursing Care of Patients with Lower Gastrointestinal Disorders
Chapter 34 Nursing Care of Patients with Lower Gastrointestinal Disorders Lower Gastrointestinal System Small Intestines Large Intestines Rectum Anus Constipation Fecal Mass Held In Rectum Feces Become
More informationMOVICOL Junior Powder for Solution (macrogol 3350)
MOVICOL Junior Powder for Solution (macrogol 3350) Product Name: MOVICOL Junior Product Description: Each sachet of MOVICOL Junior contains: Macrogol 3350 Sodium chloride Sodium bicarbonate Potassium chloride
More informationALVIMOPAN 0.0 OVERVIEW
ALVIMOPAN 0.0 OVERVIEW A. Alvimopan is a peripherally restricted mu-opioid receptor antagonist. B. DOSING INFORMATION : For the treatment of opioid bowel dysfunction, oral alvimopan doses between 0.5 milligrams
More informationSUCRALFATE TABLETS, USP
1234567890 10 210002 SUCRALFATE TABLETS, USP DESCRIPTION Sucralfate is an -D-glucopyranoside, -D-fructofuranosyl-, octakis-(hydrogen sulfate), aluminum complex. It has the following structural formula:
More informationAntimotility Agents for the Treatment of Clostridium difficile Diarrhea and Colitis
REVIEW ARTICLE Antimotility Agents for the Treatment of Clostridium difficile Diarrhea and Colitis Hoonmo L. Koo, 1,2 Diana C. Koo, 2 Daniel M. Musher, 1,4 and Herbert L. DuPont 1,2,3,5 1 Department of
More information